180 related articles for article (PubMed ID: 36048457)
1. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM; Agarwal N; Porta C; Lawrence NJ; Motzer R; McGregor B; Lee RJ; Jain RK; Davis N; Appleman LJ; Goodman O; Stadler WM; Gandhi S; Geynisman DM; Iacovelli R; Mellado B; Sepúlveda Sánchez JM; Figlin R; Powles T; Akella L; Orford K; Escudier B
JAMA Oncol; 2022 Oct; 8(10):1411-1418. PubMed ID: 36048457
[TBL] [Abstract][Full Text] [Related]
2. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Lee CH; Motzer R; Emamekhoo H; Matrana M; Percent I; Hsieh JJ; Hussain A; Vaishampayan U; Liu S; McCune S; Patel V; Shaheen M; Bendell J; Fan AC; Gartrell BA; Goodman OB; Nikolinakos PG; Kalebasty AR; Zakharia Y; Zhang Z; Parmar H; Akella L; Orford K; Tannir NM
Clin Cancer Res; 2022 Aug; 28(15):3248-3255. PubMed ID: 35576438
[TBL] [Abstract][Full Text] [Related]
3. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
4. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; Wang F; Mataveli F; Chang YL; van Kooten Losio M; Suarez C; Motzer RJ;
N Engl J Med; 2023 May; 388(19):1767-1778. PubMed ID: 37163623
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
[TBL] [Abstract][Full Text] [Related]
7. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ; Voss MH; Owonikoko TK; Carthon B; Srinivasan R; Bendell JC; Jenkins Y; Whiting SH; Orford K; Bennett MK; Bauer TM
Clin Cancer Res; 2022 Apr; 28(8):1540-1548. PubMed ID: 35140121
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ; Ferris RL; Gillison M; Tahara M; Argiris A; Fayette J; Schenker M; Bratland Å; Walker JWT; Grell P; Even C; Chung CH; Redman R; Coutte A; Salas S; Grant C; de Azevedo S; Soulières D; Hansen AR; Wei L; Khan TA; Miller-Moslin K; Roberts M; Haddad R
JAMA Oncol; 2023 Jun; 9(6):779-789. PubMed ID: 37022706
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
Apolo AB; Powles T; Escudier B; Burotto M; Zhang J; Simsek B; Scheffold C; Motzer RJ; Choueiri TK
Eur J Cancer; 2022 Dec; 177():63-71. PubMed ID: 36327527
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK
ESMO Open; 2024 Apr; 9(5):102994. PubMed ID: 38642472
[TBL] [Abstract][Full Text] [Related]
12. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
13. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
[TBL] [Abstract][Full Text] [Related]
17. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
[TBL] [Abstract][Full Text] [Related]
18. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
20. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
